| Date | Form | Description | Docs | XBRL | Pages |
| 12/08/22 | 8-K | Current report filing |
|
|
5 |
| 11/01/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 09/30/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 09/29/22 | 8-K | Current report filing |
|
|
14 |
| 09/19/22 | EFFECT | Notice of Effectiveness |
|
1 | |
| 09/16/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 09/16/22 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 09/15/22 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 09/14/22 | UPLOAD | SEC-generated letter |
|
1 | |
| 09/12/22 | DEL AM | Separately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statement |
|
1 |
Latest News & Events
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Read More...Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Read More...Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
Read More...